超越2型糖尿病的甲胺:新兴和潜在的新适应症
1School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Diabetes, obesity & metabolism
|July 5, 2024
概括
甲胺是2型糖尿病的基石,它在主要用途之外也显示出有前途. 研究探讨了其在多囊性卵巢综合征,怀孕,糖尿病前期甚至癌症预防和健康衰老方面的潜力.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 代谢疾病 代谢疾病
- 在瘤学瘤学.
背景情况:
- 甲胺是一种广泛使用的药物,主要用于2型糖尿病.
- 它的确定的好处延伸到多囊性卵巢综合征,妊娠期糖尿病,糖尿病前期预防和1型糖尿病的辅助治疗.
- 由于历史试验数据早于现代基于证据的医学标准,一些当前的用途是非标签的.
研究的目的:
- 审查梅特福林在2型糖尿病之外的既定和新兴的临床应用.
- 突出正在进行的研究,以重塑梅特福明在各种疾病中的用途.
- 为了强调该药物的长期临床实用性和未来潜力.
主要方法:
- 审查现有的临床数据和正在进行的调查研究.
- 对甲福明的作用机制的分析,包括对胰岛素敏感性和体重的影响.
- 对既有和潜在的治疗适应症的证据的审查.
主要成果:
- 甲福明在临床上用于多囊性卵巢综合征,妊娠期糖尿病,糖尿病前期以及作为1型糖尿病的辅助剂.
- 新兴的研究调查了甲胺用于癌症预防,脏保护,阿尔茨海默病,脂肪肝疾病和健康的衰老.
- 已确定的用途得到了长期临床经验的支持,尽管有些人早于当代基于证据的医学.
结论:
- 甲胺具有广泛的治疗范围,远远超出了2型糖尿病的管理范围.
- 目前正在进行的研究继续发现新的应用,这表明甲胺在各种医疗领域的未来有着重要的作用.
- 该药物的既定安全性和多方面的机制支持其持续的研究和临床应用.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:20Pathophysiology of Diabetes
917
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
917
01:15Diabetes: Symptoms, Diagnosis, and Complications
521
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
521
01:24Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
01:15Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256